Nippon Shinyaku Co Ltd   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Kyoto Japan (1911)

Organization Overview

First Clinical Trial
2002
NCT00094003
First Marketed Drug
2020
viltolarsen (Viltepso)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Funded by Toyo Shinyaku Co Ltd | NIPPON SHINYAKU | Nippon Shinyaku Co., Ltd. | NS Pharma, Inc. | Toyo Shinyaku Co Ltd

Active Ingredients

Marketed Drugs (1)

viltolarsen (Viltepso) (2020)

Drugs in Phase 4 Trials (3)

alpha-1 antitrypsin (Prolastin) (1 trial)

tadalafil (cialis) (1 trial)

viltolarsen (Viltepso) (8 trials)

Drugs in Phase 2 Trials (2)

ns-018 (2 trials)

ns-089/ncnp-02 (2 trials)

Drugs in Phase 1 Trials (1)

poly-iclc (1 trial)

Drugs in Other Trials (1)

pine bark extract (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperplasia (Phase 4)

Liver Neoplasms (Phase 1)

Muscular Dystrophies (Phase 4)

Muscular Dystrophy, Duchenne (Phase 4)

Neoplasm Metastasis (Phase 1)

Neoplasm Recurrence, Local (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Second Primary (Phase 1)

Polycythemia (Phase 2)

Polycythemia Vera (Phase 2)

Primary Myelofibrosis (Phase 2)

Prostatic Hyperplasia (Phase 4)

Recurrence (Phase 1)

Thrombocythemia, Essential (Phase 2)

Thrombocytosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 7